Efficacy and Functional Assay
Rdcthera is a leader in the research and development of radiopharmaceuticals. Our contention focuses on in vitro efficacy and functional assay services, specially designed to meet the special requirements expected of radiopharmaceutical companies. Under state-of-the-art operated laboratories, our seasoned scientific team provides you with thorough assessments of efficacy and functional performance of your radiopharmaceutical compounds to advance your research and development programs with confidence.
Overview of Efficacy and Functional Assays
Radiopharmaceuticals are indeed the very frontier for diagnosing and treating a wide range of diseases, particularly cancer. The radioactive isotopes constituting these molecules lend specificity to certain biological pathways involved and provide precision both in imaging and therapy applications. In vitro assays then assume extraordinary significance as they have to profile functionality and attributes of efficacy for these radiopharmaceuticals. Investigations of the radiopharmaceutical to determine whether the expected disruption activity of cancer cells, pathogenic bacteria, or viruses takes place, and that clarifies their mechanism of action and therapeutic windows.
Fig. 1. Anti-tumor efficacy and SPECT/CT imaging of 177Lu-SN201. (Yao Mattisson I, et al., 2023)
Comprehensive Efficacy and Functional Assay Services
We have comprehensive services at Rdcthera to evaluate radiopharmaceutical functional properties and efficacy. In this respect, our assays would define if the prospectively developed drug could activate or inhibit certain biochemical pathways and define its potential to specifically target and eliminate cancer cells or pathogenic microorganisms. Our team of scientific experts utilizes state-of-the-art techniques and equipment to provide accurate and reliable data for our clients.
- Biochemical Pathway Activation/Inhibition Assays
We define the interaction of radiopharmaceuticals with target-specific biochemical pathways. We test if they activate or inhibit significant processes involved in the development of diseases or treatments.
Our assays measure the potency of radiopharmaceuticals in killing cancer cells using several cell lines to deliver robust comprehensive data.
Rdcthera has developed numerous tumor cell lines and organ models used for assessing tumor inhibition potency.
We perform detailed mechanistic studies on the modes of action of radiopharmaceuticals to be able to understand and further optimize their design and application.
Our In Vitro Models
We exploit several in vitro models of complex biological environments in which radiopharmaceuticals act.
We investigate radiopharmaceutical efficacy and function using in vitro two-dimensional and three-dimensional cell culture systems that closely mimic in vivo conditions, enabling the generation of more relevant data.
Our organotypic culture models are specifically designed to reproduce the architecture and microenvironment of certain tissues, they can answer more deeply on radiopharmaceutical interactions and effects.
Data and Information
In vitro Efficacy and Functional Assays provide valuable data and information on MoA, target specificity, and therapeutic potential of the drug to our clients. This information shall thus be very essential in guiding informed decisions in drug development and preclinical studies.
- Quantitative Measurements
- Mechanistic Understanding
- Optimization Recommendations
Applications of In Vitro Efficacy and Functional Assays
These extend to in vitro efficacy and functional assays applied to radiopharmaceutical research across a very broad spectrum of diseases, in the areas of oncology and infectious disease. In general, this constitutes a full slate of services needed for drug discovery, from pre-clinical research through regulatory filing. Because such tests are conducted on radiopharmaceutical activity or properties in vitro, valuable insight into their potential therapeutic effect and mechanism of action can be easily had.
For more information about our in vitro efficacy and functional assay services for radiopharmaceuticals, please contact us at Rdcthera. Our dedicated team is ready to assist you with any inquiries and discuss how we can support your drug development and research efforts.
Reference
- Yao Mattisson I, Bäckström S, Ekengard E, et al. (2023). Characterization and Efficacy of a Nanomedical Radiopharmaceutical for Cancer Treatment. ACS Omega. 8(2):2357-2366.
For research use only. Not intended for any clinical use.
Related Service
